|
RS65492B1
(sr)
|
2017-07-24 |
2024-05-31 |
Novartis Ag |
Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp
|
|
MX2020001776A
(es)
|
2017-08-15 |
2020-03-24 |
Inflazome Ltd |
Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
|
|
US11623922B2
(en)
|
2017-10-03 |
2023-04-11 |
Inflazome Limited |
Compounds
|
|
EP3817815A1
(en)
*
|
2018-07-03 |
2021-05-12 |
Novartis AG |
Nlrp modulators
|
|
CN112654350A
(zh)
*
|
2018-07-03 |
2021-04-13 |
诺华股份有限公司 |
使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法
|
|
GB201902327D0
(en)
|
2019-02-20 |
2019-04-03 |
Inflazome Ltd |
Novel compounds
|
|
US12187702B2
(en)
|
2018-08-15 |
2025-01-07 |
Inflazome Limited |
Sulfonamideurea compounds
|
|
EP3880666B1
(en)
|
2018-11-13 |
2023-06-28 |
Novartis AG |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
CR20210235A
(es)
*
|
2018-11-13 |
2021-06-30 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
|
|
US20230059136A1
(en)
*
|
2018-11-16 |
2023-02-23 |
Novartis Ag |
The compounds and compositions for treating conditions associated with nlrp activity
|
|
GB201819083D0
(en)
|
2018-11-23 |
2019-01-09 |
Inflazome Ltd |
Novel compounds
|
|
GB201905265D0
(en)
|
2019-04-12 |
2019-05-29 |
Inflazome Ltd |
Inflammasome inhibition
|
|
US20220378801A1
(en)
|
2019-06-21 |
2022-12-01 |
Ac Immune Sa |
Novel compounds
|
|
WO2021002887A1
(en)
*
|
2019-07-02 |
2021-01-07 |
Novartis Inflammasome Research, Inc. |
Gut-targeted nlrp3 antagonists and their use in therapy
|
|
EP4013761A1
(en)
|
2019-08-16 |
2022-06-22 |
Inflazome Limited |
Macrocyclic sulfonylurea derivatives useful as nlrp3 inhibitors
|
|
CN114555609A
(zh)
|
2019-08-16 |
2022-05-27 |
英夫拉索姆有限公司 |
用作nlrp3抑制剂的大环磺酰胺衍生物
|
|
JP2022547882A
(ja)
|
2019-09-06 |
2022-11-16 |
インフレイゾーム リミテッド |
Ｎｌｒｐ３阻害剤
|
|
JP2023513935A
(ja)
|
2020-02-18 |
2023-04-04 |
インフレイゾーム リミテッド |
化合物
|
|
EP4132505A4
(en)
|
2020-03-25 |
2024-04-24 |
Olatec Therapeutics, Inc. |
Method for treating diabetes
|
|
MX2022014709A
(es)
|
2020-06-19 |
2022-12-16 |
Ac Immune Sa |
Derivados de dihidrooxazol y tiourea que modulan la ruta del inflamasoma de la proteina 3 que contiene el dominio pirina de la familia del receptor similar al dominio de oligomerizacion de union a nucleotido (nlrp3).
|
|
WO2022023907A1
(en)
|
2020-07-31 |
2022-02-03 |
Novartis Ag |
Methods of selecting and treating patients at elevated risk of major adverse cardiac events
|
|
US11932630B2
(en)
|
2021-04-16 |
2024-03-19 |
Novartis Ag |
Heteroaryl aminopropanol derivatives
|
|
TWI815439B
(zh)
*
|
2021-05-10 |
2023-09-11 |
大陸商成都百裕製藥股份有限公司 |
醯胺衍生物及其應用
|
|
CN118541366A
(zh)
|
2021-12-22 |
2024-08-23 |
Ac免疫有限公司 |
二氢噁唑衍生物化合物
|
|
JP2025524640A
(ja)
|
2022-07-14 |
2025-07-30 |
エーシー・イミューン・エス・アー |
Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
|
|
CA3261365A1
(en)
|
2022-07-28 |
2024-02-01 |
Ac Immune Sa |
NEW COMPOUNDS
|
|
KR20260027946A
(ko)
|
2023-06-02 |
2026-03-03 |
머크 샤프 앤드 돔 엘엘씨 |
Nod-유사 수용체 단백질 3의 억제제로서 유용한 5,6 불포화 비시클릭 헤테로사이클
|
|
WO2025133307A1
(en)
|
2023-12-22 |
2025-06-26 |
Ac Immune Sa |
Heterocyclic modulators of the nlrp3 inflammasome pathway
|
|
WO2025153532A1
(en)
|
2024-01-16 |
2025-07-24 |
NodThera Limited |
Nlrp3 inhibitors and glp-1 agonists combination therapies
|
|
WO2025153624A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025153625A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025163069A1
(en)
|
2024-01-31 |
2025-08-07 |
Ac Immune Sa |
Novel compounds
|
|
WO2026057747A1
(en)
|
2024-09-11 |
2026-03-19 |
Ac Immune Sa |
Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds
|
|
CN119680348A
(zh)
*
|
2025-02-05 |
2025-03-25 |
上海惠志环保科技有限公司 |
一种应用于含高浓度二氯甲烷废气处理方法及其系统
|